Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Macrogenics (MGNX)

Macrogenics (MGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MarketBeat.com
MacroGenics Eyes $200M Cash Boost, 2028 Runway Ahead of Cancer Pipeline Updates MarketBeat - Wed May 27, 5:05AM CDT

MacroGenics (NASDAQ:MGNX) Chief Executive Officer Eric Risser said the biotechnology company has strengthened its balance sheet through two recent transactions while preparing for a series of clinical...

MGNX : 3.98 (-0.75%)
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum GlobeNewswire - Thu May 14, 3:01PM CDT

ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,...

MGNX : 3.98 (-0.75%)
MacroGenics: Q1 Earnings Snapshot AP - Wed May 13, 3:26PM CDT

MacroGenics: Q1 Earnings Snapshot

MGNX : 3.98 (-0.75%)
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation GlobeNewswire - Wed May 13, 3:01PM CDT

Manufacturing operations divestiture sharpens focus on core capabilities in novel drug discovery and development Manufacturing divestiture and expanded monetization of ZYNYZ royalty anticipated to provide...

MGNX : 3.98 (-0.75%)
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals GlobeNewswire - Mon May 11, 4:20PM CDT

•MacroGenics to receive $122.5 million upfront payment from Bora upon closing •Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora ROCKVILLE, MD,...

MGNX : 3.98 (-0.75%)
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement GlobeNewswire - Mon May 4, 6:30AM CDT

ROCKVILLE, MD, May 04, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment...

MGNX : 3.98 (-0.75%)
FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study GlobeNewswire - Wed Apr 8, 3:30PM CDT

• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers   • On track to provide mid-2026 program update  ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenics,...

MGNX : 3.98 (-0.75%)
MacroGenics: Q4 Earnings Snapshot AP - Mon Mar 9, 3:23PM CDT

MacroGenics: Q4 Earnings Snapshot

MGNX : 3.98 (-0.75%)
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures GlobeNewswire - Mon Mar 9, 3:01PM CDT

Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026 Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026 Lorigerlimab Phase 2 LINNET study update in mid-2026 IND submission for...

MGNX : 3.98 (-0.75%)
MacroGenics to Participate in Upcoming Investor Conferences GlobeNewswire - Thu Feb 26, 4:30PM CST

ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,...

MGNX : 3.98 (-0.75%)

Barchart Exclusives

These 3 Quality Stocks Will Make You Want to LEAP on Their Calls Barchart - 11 minutes ago
Thursday’s unusual options activity had plenty to choose from. However, it was the LEAPS that were really worth considering for bullish investors. Of the 28 calls over 365 days, these three quality stocks stood out. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.